CN1042029C - 1,4－(二苯基烷基)哌嗪衍生物及含有它的药物组合物 - Google Patents

1,4－(二苯基烷基)哌嗪衍生物及含有它的药物组合物 Download PDF

Info

Publication number
CN1042029C
CN1042029C CN94192903A CN94192903A CN1042029C CN 1042029 C CN1042029 C CN 1042029C CN 94192903 A CN94192903 A CN 94192903A CN 94192903 A CN94192903 A CN 94192903A CN 1042029 C CN1042029 C CN 1042029C
Authority
CN
China
Prior art keywords
compound
compounds
salts
cranial nerve
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN94192903A
Other languages
English (en)
Chinese (zh)
Other versions
CN1128026A (zh
Inventor
河嶋洋一
松本顺三
松野圣
千田俊彦
平野佳子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MS Science Corp
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of CN1128026A publication Critical patent/CN1128026A/zh
Application granted granted Critical
Publication of CN1042029C publication Critical patent/CN1042029C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN94192903A 1993-07-28 1994-07-25 1,4－(二苯基烷基)哌嗪衍生物及含有它的药物组合物 Expired - Fee Related CN1042029C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP185839/93 1993-07-28
JP18583993 1993-07-28

Publications (2)

Publication Number Publication Date
CN1128026A CN1128026A (zh) 1996-07-31
CN1042029C true CN1042029C (zh) 1999-02-10

Family

ID=16177784

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94192903A Expired - Fee Related CN1042029C (zh) 1993-07-28 1994-07-25 1,4－(二苯基烷基)哌嗪衍生物及含有它的药物组合物

Country Status (11)

Country Link
US (1) US5736546A (enExample)
EP (1) EP0711763B1 (enExample)
KR (1) KR100299734B1 (enExample)
CN (1) CN1042029C (enExample)
AT (1) ATE197047T1 (enExample)
CA (1) CA2168264A1 (enExample)
DE (1) DE69426157T2 (enExample)
ES (1) ES2151930T3 (enExample)
FI (1) FI960364A0 (enExample)
NO (1) NO960270D0 (enExample)
WO (1) WO1995004050A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859295A (en) * 1994-12-05 1999-01-12 University Of Kentucky Research Foundation Canavanine analogs and their use as chemotherapeutic agents
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
HUP9601331A3 (en) * 1996-05-17 2000-06-28 Egyt Gyogyszervegyeszeti Gyar Piperazine- and homopiperazine-derivatives, process for producing them and pharmaceutical compositions containing them
EP0912515B1 (en) * 1996-07-10 2002-11-13 Schering Corporation 1,4-di-substituted piperidines as muscarinic antagonists
US5952349A (en) * 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5860391A (en) * 1996-08-06 1999-01-19 First Brands Corporation Absorbents containing activated carbons
US6713651B1 (en) * 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
EP1130018B1 (en) * 1998-11-09 2007-01-17 Santen Pharmaceutical Co., Ltd. Drug dependence remedy
AU5569800A (en) * 1999-06-30 2001-01-31 Santen Pharmaceutical Co. Ltd. Brain sigma-1 receptor-binding ligand
DE10050236A1 (de) * 2000-10-11 2002-04-25 Merck Patent Gmbh Verwendung bestimmter Substanzen, die an den Sigma-Rezeptor binden, zur Behandlung von Sarkomen und Karzinomen
CN1181065C (zh) 2002-05-08 2004-12-22 上海医药工业研究院 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用
CN1172919C (zh) * 2002-06-03 2004-10-27 上海医药工业研究院 芳烷醇哌嗪衍生物及其在制备抗抑郁症药物中的应用
US7863272B2 (en) * 2003-06-12 2011-01-04 M's Science Corporation Sigma ligands for neuronal regeneration and functional recovery
WO2005028457A1 (en) * 2003-09-23 2005-03-31 Fermion Oy Preparation of quetiapine
DE102004061593A1 (de) 2004-12-21 2006-06-22 Abbott Gmbh & Co. Kg Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung
CN101263127A (zh) * 2005-08-09 2008-09-10 株式会社爱慕知科学 哌嗪衍生物
NZ567629A (en) * 2005-09-23 2011-08-26 Ms Science Corp Piperazine derivatives useful in the treatment of discorders of the central nervous system
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
CN101448503B (zh) * 2006-01-27 2011-04-13 株式会社爱慕知科学 哌啶和哌嗪衍生物
CN101384260A (zh) * 2006-02-15 2009-03-11 株式会社爱慕知科学 哌嗪衍生物
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008060271A1 (en) * 2006-11-13 2008-05-22 M's Science Corporation Sigma ligands for neuronal regeneration and functional recovery
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8673920B2 (en) * 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9073882B2 (en) 2010-10-27 2015-07-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9056859B2 (en) 2010-10-29 2015-06-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
ES2605164T3 (es) 2011-08-19 2017-03-13 Merck Sharp & Dohme Corp. Inhibidores del canal de potasio de la médula renal externa
EP2755656B1 (en) 2011-09-16 2016-09-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8999991B2 (en) 2011-10-25 2015-04-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8999990B2 (en) 2011-10-25 2015-04-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013066714A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013066717A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9493474B2 (en) 2011-10-31 2016-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9206199B2 (en) 2011-12-16 2015-12-08 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
US9777002B2 (en) 2012-11-29 2017-10-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014099633A2 (en) 2012-12-19 2014-06-26 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9604998B2 (en) 2013-02-18 2017-03-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2968288B1 (en) 2013-03-15 2018-07-04 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP3027625B1 (en) 2013-07-31 2018-05-30 Merck Sharp & Dohme Corp. Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure
WO2015065866A1 (en) 2013-10-31 2015-05-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5583771A (en) * 1978-12-20 1980-06-24 Kanebo Ltd N-substituted trimethoxybenzylpiperazine derivative and its acid addition salt

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60155171A (ja) * 1983-12-10 1985-08-15 Wako Pure Chem Ind Ltd ポリメトキシベンジルピペラジン誘導体
JPS6133827A (ja) * 1984-07-27 1986-02-17 Mitsubishi Electric Corp 放電加工装置
JP2722250B2 (ja) * 1989-05-30 1998-03-04 興和株式会社 新規なジアミン化合物及びこれを含有する脳機能障害改善剤
WO1991009594A1 (en) * 1989-12-28 1991-07-11 Virginia Commonwealth University Sigma receptor ligands and the use thereof
EP0566189A1 (en) * 1992-04-13 1993-10-20 Akzo N.V. Psychotropic piperazine derivative
US5428037A (en) * 1993-04-09 1995-06-27 Syntex Pharmaceuticals, Ltd. Heterocyclic derivatives in the treatment of Ischaemia and related diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5583771A (en) * 1978-12-20 1980-06-24 Kanebo Ltd N-substituted trimethoxybenzylpiperazine derivative and its acid addition salt

Also Published As

Publication number Publication date
ES2151930T3 (es) 2001-01-16
KR100299734B1 (ko) 2002-01-09
ATE197047T1 (de) 2000-11-15
EP0711763B1 (en) 2000-10-18
EP0711763A1 (en) 1996-05-15
NO960270L (no) 1996-01-23
DE69426157D1 (de) 2000-11-23
CN1128026A (zh) 1996-07-31
DE69426157T2 (de) 2001-05-17
FI960364A7 (fi) 1996-01-26
EP0711763A4 (enExample) 1996-06-12
NO960270D0 (no) 1996-01-23
WO1995004050A1 (en) 1995-02-09
FI960364L (fi) 1996-01-26
CA2168264A1 (en) 1995-02-09
US5736546A (en) 1998-04-07
FI960364A0 (fi) 1996-01-26

Similar Documents

Publication Publication Date Title
CN1042029C (zh) 1,4－(二苯基烷基)哌嗪衍生物及含有它的药物组合物
CN1271355A (zh) 杂环化合物和以其为有效成分的抗肿瘤剂
CN1068314C (zh) 三唑化合物的及其作为多巴胺d3配位体的应用
CN1028992C (zh) 1，4，-苯并硫杂吖庚因衍生物的制备方法
CN1033043A (zh) 新的抗抑郁剂的制法
CN1450998A (zh) 含铜的胺氧化酶的抑制剂
CN1829703A (zh) 作为d3/d2受体拮抗剂的(硫代)氨基甲酰基－环己烷衍生物
CN1384102A (zh) 芳烷醇哌嗪衍生物及其在制备抗抑郁症药物中的应用
CN1176080C (zh) 茚并一,萘并一和苯并环庚二氢噻唑衍生物,它们的制备以及它们作为降低食欲药的用途
CN1653063A (zh) (s)－4－氨基－5－氯－2－甲氧基－n－[1－[1－(2－四氢呋喃羰基)－4－哌啶甲基]－4－哌啶基]苯甲酰胺及其制备方法、含有该化合物的药物组合物及其中间体
CN1016420B (zh) 苯并二氢呋喃羧酰胺衍生物的制备方法
CN1061035C (zh) 苯基链烷醇胺衍生物及其制备方法和用途
CN1349521A (zh) 治疗哮喘、过敏和炎症的化合物和方法
CN1039416C (zh) 新的吡啶并[3,2－b][1,5]苯并硫代吖庚因的制备方法
CN1568321A (zh) 新的取代4－苯基－4－(1H－咪唑－2－基)－哌啶衍生物及其作为选择性非肽δ－类鸦片激动剂的用途
CN1134149A (zh) 苯基吲哚化合物
CN1101644A (zh) 噻二嗪酮
CN1043700A (zh) 用于治疗尿失禁的化合物
CN1185214C (zh) 新的茚并吲哚酮化合物,其制备方法和含有这种化合物的药物组合物
CN1227230C (zh) Nmda受体配体的前药
CN1498214A (zh) 双环胍衍生物及其治疗用途
CN1875018A (zh) 制备噻唑烷二酮的方法
CN88102650A (zh) 二芳烷基-取代的烷基胺，其制备方法用途及含该物之药剂
CN1158615A (zh) 作为5-ht1a拮抗剂的双环甲酰胺
CN1976694A (zh) 用于治疗变应性疾病的局部用制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: M. S. SCIENCE CORP.

Free format text: FORMER OWNER: SANTEN PHARMACEUTICAL CO., LTD.

Effective date: 20110216

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: OSAKA PREFECTURE, JAPAN TO: HYOGO PREFECTURE, JAPAN

TR01 Transfer of patent right

Effective date of registration: 20110216

Address after: Hyogo

Patentee after: M. S. Science Corp.

Address before: Osaka Japan

Patentee before: Santen Pharmaceutical Co., Ltd.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 19990210

Termination date: 20120725